MDLN 8-K Current Reports

Medline 8-K Report, Financial Results (Nov 4, 2026)

Medline 8-K Report, Regulation FD Disclosure (Oct 21, 2026)

Medline Inc. (MDLN) has announced a voluntary field action involving the discontinuation and market exit of all Medline Brand beds, including homecare, bariatric, and long-term care beds, along with associated accessories. This strategic move impacts the Front Line Care product category within the Medline Brand segment. The company reported that the affected products generated approximately $60 million in net sales for the twelve months ended June 27, 2026. Medline currently estimates the total costs associated with this action, including product discontinuation, inventory impairment, disposal costs, and customer credits, to be up to $220 million. These costs are anticipated to be recognized in fiscal years 2026 and 2027 and will be excluded from Adjusted EBITDA. Despite these significant costs, Medline does not expect this action to materially impact its full-year 2026 financial results or its previously issued guidance.

Medline 8-K Report, Executive Changes (Oct 15, 2026)

Medline Inc. (MDLN) filed an 8-K report on October 15, 2026, disclosing a significant change in its Board of Directors. Joseph P. Baratta, a board member, has announced his resignation, which will be effective as of December 31, 2026. This departure is directly linked to his previously announced exit from Blackstone Inc. While the company expresses gratitude for Mr. Baratta's service, investors should note that his resignation is not attributed to any disagreements concerning Medline's operations, policies, or practices. This information is crucial for understanding board composition and potential influences on corporate strategy moving forward, especially given the timing with his departure from Blackstone.

Medline 8-K Report, Financial Results (Aug 5, 2026)

Medline reported second-quarter 2026 net sales of $7.7 billion, up 11.6%, with Organic Sales up 11.5%, driven by existing customer growth and implementation of 2025 new customer signings. Reported headline profitability is distorted by two large items. The company recognized $243 million of net IEEPA tariff refund benefits in Q2, which were booked entirely in the Medline Brand segment and included in both net income and Adjusted EBITDA. Separately, a $336 million loss from the fire at the Tracy, California distribution center was excluded from Adjusted EBITDA before expected insurance recoveries. Q2 net income fell 58.3% to $139 million, and net income attributable to Medline Inc. was $60 million. Q2 Adjusted EBITDA rose 13.4% to $1.06 billion, and diluted EPS was $0.07 against Adjusted Diluted EPS of $0.50. Excluding the $243 million refund benefit, underlying Q2 Adjusted EBITDA would be roughly $817 million, about 12.6% below the prior-year $935 million, and first-half Adjusted EBITDA would be roughly $1.59 billion, about 11.6% below the prior-year $1.80 billion. This suggests core profitability weakened in the quarter due to higher operating expenses, higher cost of goods sold including tariffs, and the cost of the fire. Full-year 2026 guidance was mixed. Organic Sales growth was raised to 9.0%-10.0% from 8.5%-9.5%, reflecting strong existing and new customer demand. Adjusted EBITDA guidance was lowered to $3.3-$3.4 billion from $3.5-$3.6 billion, citing Middle East-related inflation, increased operational investment, quality remediation, and retail softness. That guidance excludes the IEEPA refund benefit, so reported results could be higher than guided. Balance sheet and cash flow were comparatively solid. First-half operating cash flow was $1.13 billion and free cash flow was $920 million, up 37.1%. Net leverage was 2.9x on a trailing basis, with total debt of $12.75 billion and cash plus short-term investments of $2.68 billion. Tax receivable agreement liabilities rose to $4.39 billion from $3.54 billion at year-end 2025, and noncontrolling interests remain significant, with $189 million of first-half net income allocated to them. Investors should weigh the strong top-line growth and cash generation against the lower underlying earnings trend, the Tracy fire's operational and financial impact, and the one-time nature of the tariff refund benefit.

Medline 8-K Report, Executive Changes (Jul 9, 2026)

Medline Inc. (MDLN) filed an 8-K on July 9, 2026, to report the upcoming retirement of its Chief Operating Officer (COO), Stephen L. Miller, effective August 30, 2026. The company cited health-related reasons for Mr. Miller's departure. Medline Inc. has initiated a search process to identify and appoint a successor to this key executive role. This announcement marks a significant change in the company's senior leadership. Investors should monitor the selection of the new COO, as this individual will play a crucial role in executing Medline's operational strategies and future growth initiatives. The transition timeline allows for a structured handover, but the market will likely be keen to understand the company's plans for ensuring operational continuity and a smooth leadership transition during this period.

Medline 8-K Report, Shareholder Vote Results (Jun 12, 2026)

Medline Inc. (MDLN) filed an 8-K on June 12, 2026, detailing the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. The primary outcomes include the election of all 12 director nominees, overwhelming approval of the Company's executive compensation on an advisory basis, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026. Importantly, stockholders also approved holding advisory votes on executive compensation annually.

Medline 8-K Report, Material Agreement (Jun 2, 2026)

Medline Inc. (MDLN) has filed an 8-K report detailing significant refinancing transactions executed on May 28, 2026. The company successfully issued $2.0 billion in aggregate principal amount of new senior secured notes, comprising $1.25 billion of 5.000% notes due 2031 and $750 million of 5.250% notes due 2033. These proceeds, along with new term loan borrowings and cash on hand, were utilized to repay existing debt, including a senior secured term loan due 2028 and a portion of its 2030 term loan facility, as well as to redeem a portion of its 2029 senior secured notes. This strategic move aims to extend debt maturities, potentially lower interest costs, and improve its overall debt structure. In parallel, Medline also amended its credit agreement to refinance its existing senior secured term loan facility due 2030 with a new approximately $2.75 billion senior secured dollar-denominated term loan facility due 2033. The company also announced a public offering of Class A common stock by certain selling stockholders, raising approximately $2.68 billion. While the debt transactions focus on capital structure optimization, the equity offering reflects potential liquidity events for major shareholders.

Medline 8-K Report, Financial Results (May 6, 2026)

Medline Inc. (Nasdaq: MDLN) reported first quarter 2026 results for the period ended March 28, 2026, showing top-line growth alongside meaningful margin and earnings compression. Net sales rose 10.7% to $7.4 billion (Organic Sales +10.1%), driven by implementation of 2025 new customer signings and growth with existing customers. However, net income fell 25.8% to $239 million, Adjusted EBITDA declined 10.6% to $776 million, and gross margin contracted roughly 250 basis points to 25.0%, reflecting higher cost of goods sold including tariffs, elevated operating expenses to support new customer growth, and a one-time employee bonus tied to the IPO. Adjusted Diluted EPS was $0.33 versus GAAP diluted EPS of $0.16. Cash generation was softer: operating cash flow fell 39.6% to $412 million and Free Cash Flow declined 45.9% to $316 million, largely due to working capital build from higher trade receivables and inventories. Net leverage stood at 3.1x Adjusted EBITDA, with cash of $2.2 billion on the balance sheet. Notably, net income attributable to noncontrolling interests was $110 million of the $239 million total, reflecting the company's Up-C structure, and the tax receivable agreement liability rose to $4.0 billion. Management raised its full-year 2026 Organic Sales growth guidance to 8.5%-9.5% from 8%-9%, while maintaining Adjusted EBITDA guidance of $3.5-$3.6 billion. The raise signals confidence in demand and customer implementations, but investors will need to weigh it against margin pressure and the company's continued heavy investment in people, infrastructure, and automation.

Medline 8-K Report, Financial Results (Feb 25, 2026)

Medline Inc. (Nasdaq: MDLN) reported fourth quarter and full year 2025 results on February 25, 2026, the first earnings release following its IPO, which was completed in the fourth quarter of 2025. Full-year net sales rose 11.5% to $28.4 billion, with Organic Sales up 10.5%, driven mainly by volume growth in both the Medline Brand and Supply Chain Solutions segments. Full-year Adjusted EBITDA grew 3.2% to $3.5 billion, but net income fell 3.6% to $1.2 billion as tariff-related cost of goods sold and higher operating costs, including headcount investments and IPO-related expenses, weighed on profitability. Fourth-quarter Adjusted EBITDA was roughly flat at $805 million, and Q4 net income declined 37.7% to $180 million, reflecting margin compression from tariffs and higher costs. Balance sheet and cash generation improved meaningfully. Net debt fell about 35% to $10.8 billion, and net leverage dropped to 3.1x from 4.9x a year earlier, helped by IPO proceeds and debt repayment. Free Cash Flow was $1.3 billion for 2025, down 8.3% year over year, as operating cash flow was roughly flat and capital expenditures rose on distribution center automation and kitting facility investments. Management guided 2026 Organic Sales growth of 8% to 9% and Adjusted EBITDA of $3.5 to $3.6 billion, implying modest Adjusted EBITDA growth versus 2025. For investors, the key tension is top-line momentum and deleveraging versus margin pressure from tariffs and rising costs. Gross margin fell to 26.4% from 27.3%, and the 2026 EBITDA guide implies limited expansion, so the investment case depends on tariff mitigation, operating leverage from new customer signings ($2.4 billion in total new annual contract value in 2025), and continued debt reduction. The new tax receivable agreement liability of $3.5 billion and the dual-class structure are also worth monitoring.

Medline 8-K Report, Material Agreement (Dec 22, 2025)

Medline Inc. (MDLN) filed an 8-K report on December 22, 2025, detailing key events surrounding its initial public offering (IPO) on December 16, 2025. The filing primarily concerns the execution of material definitive agreements essential for its transition to a publicly traded company. These agreements establish the operational and governance framework post-IPO, including the Medline Holdings Limited Partnership Agreement, a Tax Receivable Agreement, an Exchange Agreement, and a Registration Rights Agreement. Furthermore, the report announces the appointment of Todd M. Bluedorn to the Board of Directors and his role on the Audit Committee, including an RSU award. The company also formally adopted its 2025 Omnibus Incentive Plan and 2025 Employee Stock Purchase Plan. The amended Certificate of Incorporation and Bylaws, effective December 16, 2025, outline the authorized capital stock structure. Notably, the company successfully completed its IPO, issuing 248,439,654 shares of Class A Common Stock at $29.00 per share, generating significant proceeds used for debt repayment and strategic acquisitions of common units from pre-IPO owners.